Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
XIFAXAN
Generic name / active ingredient
rifaximin
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-23

Copy from the pack in hand

Source-linked reading points

  • First distinguish the 200 mg round tablet from the 550 mg oval tablet and check the use on the actual pack. mg is the labelled amount in each exact tablet; the two strengths, bottle counts, shape or antibacterial class do not let a webpage derive a tablet count, substitution, make-up use or course.
  • The label uses XIFAXAN for specific bacteria-related indications and says it is not suitable for systemic bacterial infections. A viral illness such as a cold, fever or bloody diarrhoea, or persistent/worsening symptoms cannot be used to self-decide whether to start, repeat, increase, stop or change to another antibacterial from a webpage or an old pack.
  • The label calls for caution with severe hepatic impairment and concomitant P-gp inhibitors such as cyclosporine. With liver disease, transplant/immune medicines, anti-infectives, herbs, supplements or multiple chronic medicines at home, have a pharmacist or prescriber review every actual pack and the complete medicine list; do not self-combine, alternate or substitute based on “gut medicine,” limited absorption or a similar name.
  • With difficult breathing, face/lip/throat swelling, severe or persistent diarrhoea, bloody stool, fever, marked abdominal pain, altered consciousness or another acute serious concern, use local urgent or established care promptly; do not wait for a webpage or self-try another strength, antibacterial or leftovers.

Reviewed presentation examples — compare every field

  • 200 mg labelled per tablet; 30-tablet bottle (U.S. label)NDC 65649-301-03
  • 550 mg labelled per tablet; 60-tablet bottle (U.S. label)NDC 65649-303-02

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-23
Source record
1 clickable primary-source entry point is listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image